JP2012051865A - Sedation and sleep promoter - Google Patents

Abstract

PROBLEM TO BE SOLVED: To provide a sleep promotor and a sedative containing an extract of a fish and shellfish, and a food having sleep promoting action and sedation action.SOLUTION: An effect of the extract of a fish and shellfish on physiological action is remarked, and the present inventors have found after an extensive study that an extract of a fish and shellfish has sleep extending action and further has sedation action, and thus have completed the invention. The sleep promotor and the sedative containing the extract of a fish and shellfish are provided. The sleep promotor and the sedative containing the extract of krill are provided. The sleep promotor and the sedative containing triglyceride or phospholipid are also provided.

Description

  The present invention relates to a sleep promoting agent and a sedative containing an extract of seafood. The present invention also relates to a food having a sleep promoting action and a sedative action.

  Seafood extracts are known to have various actions on living organisms, and many fish and shellfish extracts have been studied for their effects on living organisms. For example, fish and shellfish extracts are known to promote leptin secretion (Patent Document 1). The extract that promotes the secretion of leptin increases the amount of leptin secretion from adipocytes, thereby suppressing calorie intake and activating the metabolism of sugar and lipid. Therefore, obesity associated with excessive calorie intake and reduced calorie consumption can be suppressed, which is useful for prevention and treatment of metabolic syndrome such as hypertension, diabetes and hyperlipidemia.

  In addition, it is known that seafood-derived proteins have an effect of inhibiting angiotensin conversion (Patent Document 2). It is described that peptides derived from krill protein degraded by various degrading enzymes have angiotensin I converting enzyme (ACE) inhibitory activity.

  In addition, fish and shellfish-derived proteins are known to improve lipid metabolism. For example, it is described that seafood-derived proteins have a blood cholesterol lowering effect (Patent Document 3).

  On the other hand, in recent years, the number of patients with sleep maintenance disorder and insomnia is increasing, which is a big social problem. Studies on the relationship between these diseases and the central nervous system have been actively conducted, and it is known that various substances affect the sleep action. For example, it is known that an endogenous uridine derivative has a sleep action (Patent Document 4).

  In addition, histidine-related dipeptides centered on carnosine are known to have an effect of prolonging sleep, and sleep aids containing dipeptides containing at least one of histidine and histidine derivatives as active ingredients are described ( Patent Document 5).

  In addition, it is known that the occurrence of snoring is suppressed by taking glycine (Patent Document 6). Furthermore, glycine has been described to suppress sleep apnea and to suppress a decrease in arterial oxygen saturation due to sleep apnea, and it is a snoring containing a compound having an agonistic action on a glycine receptor as an active ingredient. Or the preventive / therapeutic agent of the respiratory disorder at the time of sleep is described.

JP 2008-239500 A JP 2010-024165 A JP 2010-95456 JP JP-A-5-59087 JP2008-088162 JP 2006-191933 A

  An object of this invention is to provide the sleep promoting agent and sedative containing the extract of seafood. Another object of the present invention is to provide a food having a sleep promoting action and a sedative action.

  The present inventors paid attention to the effect of fish and shellfish extracts on physiological effects and, as a result of repeated research, found that the fish and shellfish extracts have an action of prolonging sleep. Furthermore, the present inventors have found that fish and shellfish extracts have a sedative action and have arrived at the present invention.

  That is, the present invention provides a sedation and sleep promoting agent containing a seafood extract.

  Moreover, this invention provides the said sleep promoting agent whose seafood extract is a krill extract.

  In addition, the present invention provides the sleep promoting agent, wherein the seafood extract is a triglyceride derived from seafood, a phospholipid, or a fraction containing them.

  Furthermore, the present invention provides sedation and sleep promoting agents containing triglycerides, phospholipids or polyunsaturated fatty acids.

  Furthermore, the present invention provides a food (functional food) containing a seafood extract, a triglyceride, a phospholipid, or a polyunsaturated fatty acid and labeled as having a sleep promoting action or a sedative action.

  Furthermore, the present invention provides the use of a seafood extract, triglyceride, phospholipid or polyunsaturated fatty acid to produce a food with an indication that it has a sleep promoting action or a sedative action.

  Furthermore, the present invention provides a product in which a food containing a seafood extract, triglyceride, phospholipid or polyunsaturated fatty acid is packaged together with instructions describing that the food has a sleep promoting action or a sedative action. To do.

  Since the sleep promoting agent and food containing the fish and shellfish extract of the present invention have the action of prolonging sleep, sleep can be improved. Moreover, the sleep promoter and food containing the seafood extract of the present invention have a sedative effect.

The figure which shows the influence which a krill extract has on pentobarbital sleep prolongation. The figure which shows the dose dependence of the effect which a krill extract has on pentobarbital sleep prolongation. The figure which shows the influence which a lecithin has on pentobarbital sleep prolongation. The figure which shows the influence which a krill extract has on the amount of spontaneous movements. The figure which shows the body temperature fall effect | action of a krill extract. The figure which shows the influence which phosphatidylserine fraction K-PS and phosphatidylcholine fraction K-PC have on pentobarbital sleep prolongation. The figure which shows the influence which the phosphatidylserine fraction K-PS and the phosphatidylcholine fraction K-PC exert on the locomotor activity. The figure which shows the influence which LPCE, EPA, and DHA have on pentobarbital sleep prolongation. The figure which shows the influence which LPCE, EPA, and DHA exert on spontaneous exercise amount.

  Hereinafter, the sedation and sleep promoter of the present invention will be described. The sedation and sleep promoting agent of the present invention contains a seafood extract. The seafood extract can be an extract derived from any seafood. For example, it can be an extract derived from a crustacean belonging to the order of krill, krill, in particular Euphausia superba. In addition, seafood in various states such as raw, mukimi, surimi, frozen product, dried product, and freeze-dried product can be used as the seafood product.

  The seafood extract can be extracted from the seafood by any method. For example, as shown in the examples below, seafood is heated and separated into a fat-soluble fraction, a water-soluble fraction and a solid by centrifugation. At this time, the fat-soluble fraction usually has a high triglyceride content. Further, when the water-soluble fraction is further mixed with an organic solvent and centrifuged, a fraction having a high phospholipid content is usually obtained. For example, when krill is treated by the above procedure, a fraction in which about 90% is triglyceride can be obtained as a fat-soluble fraction. In addition, a fraction in which about 80% is phospholipid can be obtained as the organic solvent fraction.

  More specifically, the krill oil used in the present invention may be produced by any method as long as it has the above-mentioned characteristics, and is described in, for example, WO 2010/035749 and WO 2010/035750. It can manufacture with reference to a well-known method. At least the lipid produced by the method described in International Publication No. 2010 / 035749A1 and International Publication No. 2010 / 035750A1 can be preferably used as the krill oil of the present invention. Krill oil can be obtained, for example, by extracting with a suitable organic solvent from the solid content as a raw material derived from krill. Suitable organic solvents include, for example, alcohols such as methanol, ethanol, propanol, isopropanol, butanol, propylene glycol or butylene glycol, methyl acetate, ethyl acetate, acetone, chloroform, toluene, pentane, hexane or cyclohexane alone or 2 A combination of two or more species, preferably ethanol or a hexane-ethanol mixture. At that time, the mixing ratio of the solvent and the ratio of the raw material to the solvent may be arbitrarily set.

  The solid content as the krill-derived raw material can be obtained, for example, by obtaining a compressed liquid by squeezing the whole krill or a part thereof, and heating the compressed liquid to separate the solid content and the water-soluble component. .

  In the above squeezing, generally used equipment can be used. For example, a hydraulic squeezing machine, a screw press, a meat mining machine, a press dehydrator, a centrifuge, or the like can be used.

  The pressing solution may be heated at 50 ° C. or higher, preferably 70 to 150 ° C., particularly preferably 85 to 110 ° C. under atmospheric pressure, pressurized or reduced pressure. The solid content and the water-soluble component are separated by this heating, and the solid content is obtained by filtration or centrifugation.

  Further, lipids may be extracted from this solid content or dried product thereof. The lipid extraction method is not particularly limited as long as it is a commonly used method, but a solvent extraction, separation and removal of protein components by pH adjustment or enzyme treatment, supercritical extraction, or the like, or a combination of these methods is used. Preferably, extraction with an organic solvent, extraction with an organic solvent after enzyme treatment, or supercritical carbon dioxide extraction is used. As the solvent used in the solvent extraction, a suitable organic solvent, for example, alcohols such as methanol, ethanol, propanol, isopropanol, butanol, propylene glycol or butylene glycol, methyl acetate, ethyl acetate, acetone, chloroform, toluene, pentane, hexane or Cyclohexane and the like can be used alone or in combination of two or more. Preferably, lipids are extracted using a hexane = ethanol mixture. At this time, the solvent mixing ratio or the raw material: solvent ratio may be set arbitrarily. The enzyme used in the enzyme treatment is not particularly limited as long as it is used in foods. However, proteases such as Alcalase (registered trademark) (manufactured by Novozyme), protease A, M, P, pancreatin F (Amano) Enzyme) etc. are used. What is necessary is just to set pH, temperature conditions, etc. of an enzyme process according to the enzyme to be used. For example, the method described in Takashi Yamashita, “New Food Processing Technology I” (Industrial Technology Association, 1986, p.204-284) can be referred to. In addition, the supercritical carbon dioxide extraction method may be carried out according to a conventional method, for example, the method described in Takashi Yamashita, “New Food Processing Technology I”, Industrial Technology Association, 1986, p. 79-102, etc. Can be helpful.

  The seafood extract used for the sedation and sleep promoter of the present invention may be any fraction of the above fat-soluble fraction and water-soluble fraction. The seafood extract can also be a mixture of a fat-soluble fraction and a water-soluble fraction.

  Further, the sedation and sleep promoting agent of the present invention is a polyvalent glyceride such as triglyceride, lysophosphatidylcholine (LPCE) or lecithin, or eicosapentaenoic acid (EPA) or docosahexaenoic acid (DHA) instead of the seafood extract. Unsaturated fatty acids can be included. The polyunsaturated fatty acid can be either n-3 or n-6. Triglycerides, phospholipids or polyunsaturated fatty acids can be produced by any method, and commercially available products can also be used.

  In this specification, promoting sleep means maintaining the homeostasis of a living body related to sleep and promoting the progression of natural sleep. The sleep promoting agent refers to one having an action of promoting sleep. Moreover, a sleep promoter means what has the effect | action which accelerates | stimulates the extension of sleep. In the present specification, sedation refers to squeezing and dropping, and includes reducing the amount of spontaneous exercise. From these actions, the agent of the present invention is effective not only for sleep promotion and sedation but also for antidepressant, anti-stress, anti-fatigue and relaxation of tension related to these.

  Moreover, the sedation and sleep promoter of this invention can be a composition containing arbitrary components in addition to said component. For example, when used as a medicament, the sedative and sleep promoting agent of the present invention is provided as a pharmaceutical composition together with a pharmaceutically acceptable base, carrier, excipient, disintegrant, lubricant, colorant and the like. can do. Examples of carriers and excipients used in the pharmaceutical composition include lactose, glucose, sucrose, mannitol, potato starch, corn starch, calcium carbonate, calcium phosphate, calcium sulfate and crystalline cellulose. Examples of the binder include starch, gelatin, syrup, tragacanth gum, polyvinyl alcohol, polyvinyl ether, polyvinyl pyrrolidone, hydroxypropylcellulose, methylcellulose, ethylcellulose and carboxymethylcellulose. Examples of the disintegrant include starch, agar, gelatin powder, crystalline cellulose, calcium carbonate, sodium hydrogen carbonate, sodium alginate, sodium carboxymethyl cellulose, carboxymethyl cellulose calcium and the like. Examples of lubricants include magnesium stearate, hydrogenated vegetable oil, talc and macrogol. As the colorant, any colorant allowed to be added to a pharmaceutical product can be used. In addition, the pharmaceutical composition may be sucrose, gelatin, purified shellac, gelatin, glycerin, sorbitol, ethylcellulose, hydroxypropylcellulose, hydroxypropylmethylcellulose, polyvinylpyrrolidone, cellulose phthalate acetate, hydroxypropylmethylcellulose phthalate, methyl methacrylate Further, it may be coated with one or more layers with a methacrylic acid polymer or the like. Moreover, you may add a pH adjuster, a buffering agent, a stabilizer, a solubilizer, etc. as needed.

  In addition, the pharmaceutical composition can be provided as a preparation in any form. For example, the pharmaceutical composition can be prepared as an orally administered preparation, such as a sugar-coated tablet, buccal tablet, coated tablet and chewable tablet, capsules including troches, pills, powders and soft capsules, granules, suspensions, emulsions and dry syrups. It can be a liquid such as syrup and elixir. In addition, the pharmaceutical composition can be administered intravenously, subcutaneously, intraperitoneally, intramuscularly, transdermally, nasally, pulmonarily, enterally, buccally, and transmucosally for parenteral administration. It can be a formulation for administration, such as administration. For example, it can be an injection, a transdermal absorption tape, an aerosol, a suppository and the like.

  Moreover, the sedation and sleep promoter of this invention can be provided as a foodstuff. That is, a food containing a seafood extract, triglyceride, phospholipid or polyunsaturated fatty acid and having a sleep promoting action or a sedative action is provided. In the present invention, food means all foods including beverages, and includes general health foods including health foods such as supplements, as well as specific health foods and nutritional functional foods stipulated in the Health Functional Food System of the Ministry of Health, Labor and Welfare. . For example, a functional food with an indication that it has a sleep promoting action or a sedative action is provided. For example, food containing the krill extract can be provided as it is. Moreover, the foodstuff which provided the sleep promoting effect or the sedative action as a foodstuff material can be provided by adding, mixing, or apply | coating to another foodstuff. In addition to food, it can also be provided as cosmetics and food.

  In addition, a food containing a seafood extract, triglyceride, phospholipid or polyunsaturated fatty acid can be provided as a product packaged with instructions describing that the food has a sleep promoting action or a sedative action. .

  In addition, seafood extracts, triglycerides, phospholipids or polyunsaturated fatty acids can be used to produce foods that are labeled as having sleep promoting or sedative effects as described above. Although it is not limited to the sedation and sleep promoter of this invention, and foodstuffs, it can contain the quantity required in order to show a sleep promotion effect or a sedation effect. The sedative and sleep promoting agents and foods of the present invention can contain seafood extracts, triglycerides, phospholipids or polyunsaturated fatty acids in any amount, for example in an amount of 100 μg to 1000 mg / kg. it can.

  In addition, fish and shellfish extracts, triglycerides, phospholipids or polyunsaturated fatty acids, when administered as a medicament to a patient, are not limited, depending on conditions such as the degree of symptoms, patient age, weight and health status, For adults, 100 μg to 1000 mg / kg / day can be administered orally or parenterally, once a day or divided into 2 to 4 times or more, and can be administered at appropriate intervals. In the case of single administration, administration is preferably performed before going to bed.

Example 1 Production of Krill Extract Krill oil can be produced, for example, by any of the methods described in WO 2010/03749 and WO 2010/03750. Specific examples of production are shown below.

  By pressing the Antarctic krill (10t) immediately after catching using a meat mining machine (Bader, model BAADER605), a pressing solution (3t) was obtained. This compressed liquid (800 kg) was stored in a stainless steel tank and heated by directly administering 140 ° C. water vapor. After confirming that the temperature of the pressing liquid reached 85 ° C. by heating for about 60 minutes, heating was stopped. The valve at the bottom of the tank was opened, the liquid component that passed through the mesh of 2 mm was removed by natural dropping, and the solid content (thermal coagulum) on the mesh was washed by showering with the same amount of water (3 t). Then, 12 kg each was stored in an aluminum tray and quickly frozen with a contact freezer.

  The frozen thermocoagulated product (1 t) was put into water (3,000 L), heated with stirring to 65 ° C., and held for 10 minutes. Water was drained using 24 mesh nylon, and the solid content was put into water (3,000 L, 20 ° C.). After stirring for 15 minutes, drain with 24 mesh nylon, and further treat with a centrifugal dehydrator (Tanabe Centrifuge O-30) for 15 seconds to obtain solids (512 kg, moisture 63.8%). Obtained. In the present invention, this sample is referred to as KC-1.

  In addition, the frozen heat-coagulated product was freeze-dried with a freeze dryer to obtain a freeze-dried product (185 kg). In the present invention, this sample is referred to as KC-3.

  Further, this KC-3 was extracted with ethanol to obtain an extract. In the present invention, this sample is called K-PC. Further, using this K-PC as a raw material, a phosphatidylserine fraction was obtained according to the method of Hosokawa et al. (J. Agric. Food Chem. 2000, 48, 4550-4554). In the present invention, this sample is called K-PS.

  On the other hand, for the krill thermocoagulated material prepared by the method described in International Publication No. 2010/03749 or International Publication No. 2010/03750, the lipid component by supercritical carbon dioxide was obtained under the conditions of 34.3 MPa and 40 ° C. Extraction was carried out to obtain an extract containing a high amount of triglycerides. In the present invention, this sample is called NT.

  Furthermore, ethanol was added to the extraction residue of this extract (NT), and lipid components were extracted again with supercritical carbon dioxide under the same conditions to obtain an extract containing a high phospholipid content. In the present invention, this sample is called NP.

  In the present invention, each lipid component separated by a developing solvent of benzene: chloroform: acetic acid = 150: 60: 1.5 is a thin layer automatic detection device (manufactured by Mitsubishi Chemical Yatron, Model Iatroscan (registered trademark)). ) Quantification using MK-6). The fatty acid composition was analyzed by gas chromatography (Agilent Technology, Model 6890N) after converting the constituent fatty acid to methyl ester in boron trifluoride. The column for gas chromatography used was J & W Scientific, DB-WAX (model number 122-7032), and helium was used as the carrier gas.

Example 2 Sleep Promoting Action of Krill Extract (Pentobarbital (PB) Sleep Prolonging Action of Krill Extract)
KC-1, KC-3, NP and NT obtained in Example 1 were orally administered to mice (10 mice per group) at 500 mg / kg. After 15 minutes, PB was intraperitoneally administered at a dose of 40 mg / kg, and the time from recovery of the right-angle reflex to recovery was measured as sleep time. In the control group (10 mice per group), physiological saline was orally administered, the same experiment was conducted, and comparative evaluation was performed. The water-soluble fraction was dissolved in physiological saline. The fat-soluble fraction was dissolved in physiological saline containing 0.1% Tween80.

Results As shown in FIG. 1, KC-1 and KC-3 did not show a significant PB sleep prolongation effect, whereas NP and NT both showed a significant PB sleep prolongation effect in oral administration. Results are shown as mean ± SE. In the figure, * indicates a significant difference (p <0.05) compared to the control. ** indicates a significant difference (p <0.01) compared to the control.

(Dose dependence on the PB sleep prolongation effect of NP)
100, 250, and 500 mg / kg were orally administered to mice (10 per group) for the NP that showed the greatest PB sleep prolongation effect in FIG. 15 minutes after administration, PB was intraperitoneally administered at 40 mg / kg, and sleep time was measured from the disappearance of the right reflex. In the control group (10 mice per group), physiological saline was orally administered, the same experiment was conducted, and comparative evaluation was performed. The water-soluble fraction was dissolved in physiological saline. The fat-soluble fraction was dissolved in physiological saline containing 0.1% Tween80.

Results As shown in FIG. 2, NP had a dose-dependent sleep prolongation effect. Results are shown as mean ± SE. In the figure, * indicates a significant difference (p <0.05) compared to the control. ** indicates a significant difference (p <0.01) compared to the control.

(Lecithin pentobarbital (PB) sleep prolongation)
Similar to the pentobarbital sleep-prolonging action of the krill extract described above, a test was conducted using lecithin derived from egg or soybean (manufactured by Wako Pure Chemical Industries, Ltd.) instead of the krill extract.

Results As shown in FIG. 3, both soybean and egg lecithin showed a significant PB sleep-prolonging effect in oral administration. Results are shown as mean ± SE. In the figure, * indicates a significant difference (p <0.05) compared to the control. ** indicates a significant difference (p <0.01) compared to the control.

(Effect of krill extract on spontaneous momentum)
KC-1, KC-3, NP and NT obtained in Example 1 were orally administered to mice (10 mice per group) at 500 mg / kg. 15 minutes after administration, the mouse is placed in the center of the hall board, and the spontaneous exercise amount is set to 1 section: 4 times every 5 minutes (20 minutes), and 3 sections (60 minutes) spontaneous exercise amount (total movement distance, number of rises, etc.) is video-tracked. Measurement was performed using a system (spontaneous momentum analyzer). In the control group (10 mice per group), physiological saline was orally administered, the same experiment was conducted, and comparative evaluation was performed. The water-soluble fraction was dissolved in physiological saline. The fat-soluble fraction was dissolved in physiological saline containing 0.1% Tween80.

Results As shown in FIG. 4, KC-1, KC-3, NP and NT all showed a tendency to decrease the amount of spontaneous exercise (total movement distance and number of rises) in oral administration. Results are shown as mean ± SE.

(The body temperature lowering effect of krill extract)
After orally administering KC-1, KC-3, NP and NT obtained in Example 1 to mice (10 mice per group) at 500 mg / kg, the rectal temperature of the mice was changed over time (0, 5, 10, 15, 30, 45, 60, 90 and 120 minutes), and the body temperature lowering effect was examined. In the control group (10 mice per group), physiological saline was orally administered, the same experiment was conducted, and comparative evaluation was performed. The water-soluble fraction was dissolved in physiological saline. The fat-soluble fraction was dissolved in physiological saline containing 0.1% Tween80.

Results As shown in FIG. 5, as a result of examining the PB sleep prolongation action and the spontaneous exercise amount, the NP that showed the effect was also found to have a body temperature lowering action. In addition, this effect showed a decrease in maximum body temperature at 45 minutes, which was in good agreement with the results of PB sleep prolongation and spontaneous exercise. Results are shown as mean ± SE.

(Pentobarbital (PB) sleep prolongation effect of phosphatidylserine fraction K-PS, phosphatidylcholine fraction K-PC and EPA-28)
Phosphatidylserine fraction K-PS, phosphatidylcholine fraction K-PC and EPA-28 (DD oil type 2; manufactured by Nihon Suisan Co., Ltd.) were orally administered to mice (10 mice per group) at 500 mg / kg. After 15 minutes, PB was intraperitoneally administered at a dose of 40 mg / kg, and the time from recovery of the right-angle reflex to recovery was measured as sleep time. In the control group (10 mice per group), physiological saline was orally administered, the same experiment was conducted, and comparative evaluation was performed. The water-soluble fraction was dissolved in physiological saline. The fat-soluble fraction was dissolved in physiological saline containing 0.1% Tween80.

Results As shown in Fig. 6, K-PS, K-PC and EPA-28 all showed PB sleep prolongation, but K-PC and K-PS showed similar prolongation. Showed the strongest effect. Results are shown as mean ± SE. In the figure, * indicates a significant difference (p <0.05) compared to the control. ** indicates a significant difference (p <0.01) compared to the control.

(Effects of phosphatidylserine fraction K-PS, phosphatidylcholine fraction K-PC and EPA-28 on locomotor activity)
The phosphatidylserine fraction K-PS, the phosphatidylcholine fraction K-PC and EPA-28 were orally administered to mice (10 mice per group) at 500 mg / kg. 15 minutes after administration, the mouse is placed in the center of the hall board, and the spontaneous exercise amount is set to 1 section: 4 times every 5 minutes (20 minutes), and 3 sections (60 minutes) spontaneous exercise amount (total movement distance, number of rises, etc.) is video-tracked. Measurement was performed using a system (spontaneous momentum analyzer). In the control group (10 mice per group), physiological saline was orally administered, the same experiment was conducted, and comparative evaluation was performed. The water-soluble fraction was dissolved in physiological saline. The fat-soluble fraction was dissolved in physiological saline containing 0.1% Tween80.

Results As shown in FIG. 7, K-PS, K-PC and EPA-28 all showed a tendency to decrease the amount of spontaneous exercise (total movement distance and number of rises) in oral administration. Results are shown as mean ± SE. In the figure, * indicates a significant difference (p <0.05) compared to the control.

(Pentobarbital (PB) sleep-prolonging action of lysophosphatidylcholine (LPCE), eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA))
LPCE (Sigma), EPA (Nihon Suisan) and DHA (Nihon Suisan) were orally administered to mice (10 mice per group) at 500 mg / kg. After 15 minutes, PB was intraperitoneally administered at a dose of 40 mg / kg, and the time from recovery of the right-angle reflex to recovery was measured as sleep time. In the control group (10 mice per group), physiological saline was orally administered, the same experiment was conducted, and comparative evaluation was performed. The water-soluble fraction was dissolved in physiological saline. The fat-soluble fraction was dissolved in physiological saline containing 0.1% Tween80.

Results As shown in FIG. 8, LPCE, EPA and DHA all exhibited PB sleep prolongation action. Results are shown as mean ± SE. In the figure, * indicates a significant difference (p <0.05) compared to the control.

(Effects of LPCE, EPA and DHA on spontaneous momentum)
LPCE, EPA and DHA were orally administered to mice (10 mice per group) at 500 mg / kg. 15 minutes after administration, the mouse is placed in the center of the hall board, and the spontaneous exercise amount is set to 1 section: 4 times every 5 minutes (20 minutes), and 3 sections (60 minutes) spontaneous exercise amount (total movement distance, number of rises, etc.) is video-tracked. Measurement was performed using a system (spontaneous momentum analyzer). In the control group (10 mice per group), physiological saline was orally administered, the same experiment was conducted, and comparative evaluation was performed. The water-soluble fraction was dissolved in physiological saline. The fat-soluble fraction was dissolved in physiological saline containing 0.1% Tween80.

Results As shown in FIG. 9, LPCE, EPA, and DHA all showed a tendency to decrease the amount of spontaneous exercise (total movement distance and number of rises) after oral administration. Results are shown as mean ± SE.

(Fatty acid content in the tested sample)
The fatty acid content in soy and egg lecithin and in K-PS, K-PC and EPA-28 was measured.

The fatty acid content of each sample was as shown in Table 1.

Claims (7)

  A sedative and sleep promoter containing a seafood extract.   2. The sedative and sleep promoting agent according to claim 1, wherein the seafood extract is a krill extract.   2. The sedative and sleep promoting agent according to claim 1, wherein the fish and shellfish extract is a fish and shellfish-derived triglyceride-rich extract or a phospholipid-rich extract.   A sedative and sleep-promoting agent containing triglycerides, phospholipids, phospholipids or polyunsaturated fatty acids.   A food containing a seafood extract, triglycerides, phospholipids or polyunsaturated fatty acids and labeled as having a sleep promoting action or a sedative action.   Use of a seafood extract, triglyceride, phospholipid or polyunsaturated fatty acid for producing a food with a label indicating that it has a sleep promoting action or a sedative action.   A product obtained by packaging a food containing a seafood extract, triglyceride, phospholipid or polyunsaturated fatty acid together with instructions describing that the food has a sleep promoting action or a sedative action.